172 related articles for article (PubMed ID: 10369945)
1. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible?
Schulte M; Brecht-Krauss D; Heymer B; Guhlmann A; Hartwig E; Sarkar MR; Diederichs CG; Schultheiss M; Kotzerke J; Reske SN
Eur J Nucl Med; 1999 Jun; 26(6):599-605. PubMed ID: 10369945
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
[TBL] [Abstract][Full Text] [Related]
5. Assessment of soft tissue lesions suspicious for liposarcoma by F18-deoxyglucose (FDG) positron emission tomography (PET).
Schwarzbach MH; Dimitrakopoulou-Strauss A; Mechtersheimer G; Hinz U; Willeke F; Cardona S; Attigah N; Strauss LG; Herfarth C; Lehnert T
Anticancer Res; 2001; 21(5):3609-14. PubMed ID: 11848531
[TBL] [Abstract][Full Text] [Related]
6. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET.
Zhang H; Tian M; Oriuchi N; Higuchi T; Watanabe H; Aoki J; Tanada S; Endo K
Nucl Med Commun; 2003 Mar; 24(3):273-9. PubMed ID: 12612468
[TBL] [Abstract][Full Text] [Related]
7. A PET study of 18FDG uptake in soft tissue masses.
Lodge MA; Lucas JD; Marsden PK; Cronin BF; O'Doherty MJ; Smith MA
Eur J Nucl Med; 1999 Jan; 26(1):22-30. PubMed ID: 9933658
[TBL] [Abstract][Full Text] [Related]
8. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET.
Watanabe H; Inoue T; Shinozaki T; Yanagawa T; Ahmed AR; Tomiyoshi K; Oriuchi N; Tokunaga M; Aoki J; Endo K; Takagishi K
Eur J Nucl Med; 2000 Oct; 27(10):1509-17. PubMed ID: 11083540
[TBL] [Abstract][Full Text] [Related]
9. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET.
Schulte M; Brecht-Krauss D; Heymer B; Guhlmann A; Hartwig E; Sarkar MR; Diederichs CG; Von Baer A; Kotzerke J; Reske SN
J Nucl Med; 2000 Oct; 41(10):1695-701. PubMed ID: 11038000
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence.
Fendler WP; Chalkidis RP; Ilhan H; Knösel T; Herrmann K; Issels RD; Bartenstein P; Cyran CC; Lindner LH; Hacker M
Eur Radiol; 2015 Aug; 25(8):2214-21. PubMed ID: 25693667
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours.
Cardona S; Schwarzbach M; Hinz U; Dimitrakopoulou-Strauss A; Attigah N; Mechtersheimer section sign G; Lehnert T
Eur J Surg Oncol; 2003 Aug; 29(6):536-41. PubMed ID: 12875862
[TBL] [Abstract][Full Text] [Related]
12. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Limitations of F-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography to Differentiate Between Malignant and Benign Bone and Soft Tissue Tumors.
Miwa S; Mochizuki T; Yamamoto N; Shirai T; Hayashi K; Takeuchi A; Inatani H; Igarashi K; Higuchi T; Abe K; Taniguchi Y; Aiba H; Ikeda H; Tsuchiya H
Anticancer Res; 2018 Jul; 38(7):4065-4072. PubMed ID: 29970532
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography.
Lucas JD; O'Doherty MJ; Cronin BF; Marsden PK; Lodge MA; McKee PH; Smith MA
Br J Surg; 1999 Apr; 86(4):550-6. PubMed ID: 10215835
[TBL] [Abstract][Full Text] [Related]
16. Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions.
Imdahl A; Jenkner S; Brink I; Nitzsche E; Stoelben E; Moser E; Hasse J
Eur J Cardiothorac Surg; 2001 Aug; 20(2):324-9. PubMed ID: 11463551
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors.
Tian M; Zhang H; Oriuchi N; Higuchi T; Endo K
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1064-72. PubMed ID: 15014903
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.
Aoki J; Watanabe H; Shinozaki T; Takagishi K; Tokunaga M; Koyama Y; Sato N; Endo K
Skeletal Radiol; 2003 Mar; 32(3):133-8. PubMed ID: 12605276
[TBL] [Abstract][Full Text] [Related]
19. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
20. Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning.
Watanabe H; Shinozaki T; Yanagawa T; Aoki J; Tokunaga M; Inoue T; Endo K; Mohara S; Sano K; Takagishi K
J Bone Joint Surg Br; 2000 Jul; 82(5):760-7. PubMed ID: 10963181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
